This article aims to provide an overview of the significant impact of FAK on both cancer cells and cancer-associated cells within tumors while also offering a comprehensive discussion of the recent advances made in developing therapeutic agents that target FAK and the combination of these agents with other approaches. This evidence concerns the gene PTK2 and cancer.